Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Ahmed N, Stenvers KL.

Front Oncol. 2013 Sep 25;3:256. doi: 10.3389/fonc.2013.00256. Review.

2.

Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations.

Katz E, Skorecki K, Tzukerman M.

Clin Cancer Res. 2009 Jan 1;15(1):70-80. doi: 10.1158/1078-0432.CCR-08-1233.

3.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N.

PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.

4.

Malignant ascites in ovarian cancer and the role of targeted therapeutics.

Smolle E, Taucher V, Haybaeck J.

Anticancer Res. 2014 Apr;34(4):1553-61. Review.

PMID:
24692682
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.
7.

Metastasis of ovarian cancer is mediated by kallikrein related peptidases.

Dong Y, Loessner D, Irving-Rodgers H, Obermair A, Nicklin JL, Clements JA.

Clin Exp Metastasis. 2014 Jan;31(1):135-47. doi: 10.1007/s10585-013-9615-4. Epub 2013 Sep 17. Review.

8.
9.

Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM.

Transl Oncol. 2010 Aug 1;3(4):230-8.

10.

Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review).

Taylor DD, Gercel-Taylor C.

Oncol Rep. 1998 Nov-Dec;5(6):1519-24. Review.

PMID:
9769398
11.

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA.

Gynecol Oncol. 2008 Feb;108(2):421-7. Epub 2007 Nov 26.

PMID:
18036640
12.

Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.

Rizvi I, Gurkan UA, Tasoglu S, Alagic N, Celli JP, Mensah LB, Mai Z, Demirci U, Hasan T.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):E1974-83. doi: 10.1073/pnas.1216989110. Epub 2013 May 3.

13.

Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).

Freedman RS, Deavers M, Liu J, Wang E.

J Transl Med. 2004 Jun 25;2(1):23.

14.

Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.

Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, Goff BA, Hanash SM, Swisher EM.

Int J Gynecol Cancer. 2012 May;22(4):546-52. doi: 10.1097/IGC.0b013e318241d9b9.

PMID:
22315094
15.

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer.

Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM.

Neoplasia. 2007 Oct;9(10):820-9.

16.

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.

Clin Cancer Res. 2003 Aug 15;9(9):3476-85.

17.

Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.

Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA.

PLoS One. 2013;8(2):e57056. doi: 10.1371/journal.pone.0057056. Epub 2013 Feb 25.

18.

Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.

Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R.

Thromb Haemost. 2011 Oct;106(4):705-11. doi: 10.1160/TH11-05-0311. Epub 2011 Aug 11.

PMID:
21833453
19.

Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells.

Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr, Odunsi K, Bankert RB.

Cancer Immun. 2013 Jul 15;13:14. Print 2013.

20.

Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.

Ahmed N, Abubaker K, Findlay J, Quinn M.

Curr Cancer Drug Targets. 2010 May;10(3):268-78. Review.

PMID:
20370691
Items per page

Supplemental Content

Write to the Help Desk